Premium
Synthesis of radiotracer for liver fibrosis
Author(s) -
Zhang Z.,
Machac J.,
Albanis E.,
Lipszye H.,
Beljaars L.,
Poelstra K.,
Friedman S. L.
Publication year - 2001
Publication title -
journal of labelled compounds and radiopharmaceuticals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.432
H-Index - 47
eISSN - 1099-1344
pISSN - 0362-4803
DOI - 10.1002/jlcr.25804401268
Subject(s) - chemistry , platelet derived growth factor receptor , hepatic stellate cell , bifunctional , receptor , fibrosis , hepatic fibrosis , downregulation and upregulation , liver fibrosis , growth factor , platelet derived growth factor , peptide , cancer research , biochemistry , pathology , medicine , gene , catalysis
Liver fibrosis (LF) is among the top ten causes of death in the western world. The traditional method for diagnosis of LF is biopsy. We are seeking a non‐invasive imaging method for the diagnosis of LF and assessment of its onset and progression. Activation of hepatic stellate cells (HSC) is a key event in fibrosis and is characterized by upregulation of receptors for platelet derived growth factor (PDGF). We exploited this property to develop a ligand that will allow us to quantitate numbers of activated HSC based on their expression of PDGF receptor. Specifically we have explored the possibility of developing HSC‐selective radiopharmaceuticals by coupling bifunctional chelators to a cyclic peptide (C*SRNLIDC*)‐HSA conjugate 1 (pPB‐HSA) 1, which is a PDGF receptor recognizing compound.